학술논문

Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma
Document Type
Article
Source
In Annals of Oncology July 2014 25(7):1384-1390
Subject
Language
ISSN
0923-7534